Kiniksa Pharmaceuticals International, plc
KNSA · XNASCIK 1730430fmd_0QH2HGF8585HECYAWVSHVGR12SManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 38 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 39 | 220 | 270 | 423 | 678 |
| Cost of revenue | – | – | – | – | 9 | 23 | 33 | 61 | 78 |
| Gross profit | – | – | – | – | 29 | 197 | 237 | 362 | 600 |
| Research and development | 56 | 87 | 135 | 112 | 99 | 65 | 76 | 112 | 97 |
| Selling, general and administrative | – | – | 35 | 45 | 86 | 98 | 129 | 168 | 196 |
| Total operating expenses | 65 | 108 | 170 | 157 | – | – | – | – | – |
| Operating income | (65) | (108) | (170) | (157) | (157) | 10 | (25) | (46) | 77 |
| Interest and investment income | 1 | 5 | 6 | 1 | 0 | 1 | 8 | 9 | 12 |
| Income before taxes | (65) | (103) | (164) | (156) | (157) | 11 | (17) | (36) | 89 |
| Income tax expense | 0 | (0) | (2) | 5 | 1 | (172) | (31) | 7 | 30 |
| Net income from continuing operations | (65) | (103) | (162) | (161) | (158) | 183 | 14 | (43) | 59 |
| Net income | (65) | (103) | (162) | (161) | (158) | 183 | 14 | (43) | 59 |